A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. The biological processes leave measurable traces in the blood, but only for a limited period.
The discovery thus reveals a window of opportunity that could be crucial for future treatment, but also for early diagnosis via blood tests, which could begin to be tested in health care within five years.
Parkinson’s is an endemic disease with over 10 million people affected globally. As the world’s population grows older, this number is expected to more than double by 2050. At present, there is neither an effective cure nor an established screening method for detecting this chronic neurological disorder at an early stage before it has caused significant damage to the brain.









